|
| All patients (N = 106) (%) | BMPCs before PBSC mobilization | P value |
| <5% (N = 73) | ≥5% (N = 33) |
|
| Baseline characteristics | | | | |
| Age, years, median (range) | 56 (33–65) | 56 (34–65) | 56 (33–65) | ns |
| Patient gender (M/F) | 59 (56)/47 (44) | 39 (53)/34 (47) | 20 (61)/13 (39) | ns |
| Serum M protein | | | | ns |
| Light chain | 30 (28) | 20 (28) | 10 (30) | |
| Other than light chain | 76 (72) | 53 (72) | 23 (70) | |
| Stage at diagnosis | | | | ns |
| IIA | 6 (6) | 6 (8) | 0 (0) | |
| IIIA/B | 100 (94) | 67 (92) | 33 (100) | |
| Cytogenetics* | | | | ns |
| Standard risk | 88 (83) | 63 (86) | 25 (76) | |
| High risk | 18 (17) | 10 (14) | 8 (24) | |
| BMPCs at diagnosis, %, median (range) | 39 (3–90) | 38 (3–88) | 42.3 (8–90) | ns |
| Myeloma bone disease on plain radiographs, yes/no | 81 (76)/25 (24) | 58 (80)/15 (20) | 23 (70)/10 (30) | ns |
| Serum calcium at diagnosis, mg/dL, median (range) | 8.9 (6.8–16.2) | 8.9 (6.8–15.7) | 9.0 (7.4–16.2) | ns |
| Serum creatinine at diagnosis, mg/dL, median (range) | 0.9 (0.4–8.3) | 0.9 (0.4–8.3) | 0.9 (0.5–5.6) | ns |
| β2-microglobulin at diagnosis, mg/mL, median (range) | 3.5 (0.2–41.4) | 3.5 (0.2–41.4) | 3.8 (1.6–36.0) | ns |
| Hemoglobin at diagnosis, g/dL, median (range) | 9.8 (6.0–17.2) | 9.8 (6.0–17.2) | 9.5 (6.5–14.8) | ns |
| Serum lactate dehydrogenase at diagnosis, U/L, median (range) | 374 (81–1054) | 389 (165–1054) | 361 (81–889) | ns |
|
| Treatment and outcomes | | | | |
| Induction therapy | | | | 0.039 |
| Bortezomib ± dexamethasone | 51 (48) | 36 (49) | 15 (46) | |
| Bortezomib + thalidomide + dexamethasone | 12 (11.5) | 8 (11) | 4 (12) | |
| Thalidomide + dexamethasone | 31 (29) | 17 (23) | 14 (42) | |
| High-dose dexa-based regimen | 12 (11.5) | 12 (17) | 0 (0) | |
| Duration from diagnosis to ASCT, months, median (range) | 6.7 (2.9–15.6) | 6.9 (2.9–15.6) | 6.1 (3.9–15.3) | ns |
| Maintenance therapy after ASCT | | | | 0.742 |
| Yes | 73 (69) | 51 (70) | 22 (67) | |
| Thalidomide | 50 (47) | 35 (48) | 15 (46) | |
| Bortezomib or Lenalidomide | 8 (8) | 3 (4) | 5 (15) | |
| Prednisolone | 15 (14) | 13 (18) | 2 (6) | |
| No | 33 (31) | 22 (30) | 11 (33) | |
| Serologic response before PBSC mobilization | | | | <0.001 |
| CR | 39 (37) | 35 (48) | 4 (12) | |
| VGPR | 38 (36) | 25 (34) | 13 (39.5) | |
| PR | 25 (23) | 12 (17) | 13 (39.5) | |
| SD | 4 (4) | 1 (1) | 3 (9) | |
| Serologic response after PBSC mobilization | | | | <0.001 |
| CR | 47 (44) | 41 (56) | 6 (18) | |
| VGPR | 36 (34) | 22 (30) | 14 (42) | |
| PR | 20 (19) | 10 (14) | 10 (30) | |
| SD | 3 (3) | 0 (0) | 3 (9) | |
|
